Apellis Pharmaceuticals Inc (APLS)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$24.60
Buy
$25.78
$0.17 (+0.69%)
Prices updated at 19 Dec 2025, 22:05 EST
| Prices minimum 15 mins delay
Prices in USD
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 84.93 |
| 2023 | 85.25 |
| 2022 | 92.53 |
| 2021 | 92.19 |
| 2020 | 90.01 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 3.12 |
| 2024 | 5.49 |
| 2023 | 25.45 |
| 2022 | 46.42 |
| 2021 | 14.82 |
| 2020 | 5,920.96 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
Price/Forward earnings (YTD)
-18.83
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -23.64 |
| 2023 | -68.26 |
| 2022 | -79.44 |
| 2021 | -81.02 |
| 2020 | -51.10 |
| 2019 | -102.81 |
| 2018 | -66.12 |
| 2017 | -48.68 |
| 2016 | -82.68 |
| 2015 | -177.26 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 3.87 |
| 2023 | 4.05 |
| 2022 | 4.48 |
| 2021 | 4.44 |
| 2020 | 4.70 |
| 2019 | 11.37 |
| 2018 | 1.26 |
| 2017 | 1.22 |
| 2016 | - |
| 2015 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
